2 weeks Ago By Defense World Staff
Shares of Cellebrite DI Ltd. ( NASDAQ:CLBT – Get Free Report ) have been assigned a consensus rating of “Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating.
The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $18.57. A number of brokerages have commented on CLBT.
JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $14.00 to $15.
00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Lake Street Capital upped their price target on shares of Cellebrite DI from $13.50 to $17.
00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Craig Hallum boosted their price target on Cellebrite DI from $20.00 to $23.
00 and gave the stock a “buy” rating in a research note on Wednesday. Needham & Company LLC increased their price objective on shares of Cellebrite DI from $14.00 to $17.
00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Bank of America upped their price objective on Cellebrite DI from $13.00 to $17.
00 and gave the company a “buy” rating in a research report on Friday, August 16th. View Our Latest Analysis on CLBT Hedge Funds Weigh In On Cellebrite DI Cellebrite DI Stock Down 2.1 % NASDAQ:CLBT opened at $16.
85 on Friday. The stock’s fifty day moving average is $15.61 and its two-hundred day moving average is $12.
85. Cellebrite DI has a 52 week low of $6.36 and a 52 week high of $17.
82. The company has a market capitalization of $3.47 billion, a P/E ratio of -29.
05, a P/E/G ratio of 2.32 and a beta of 1.52.
Cellebrite DI ( NASDAQ:CLBT – Get Free Report ) last released its earnings results on Thursday, August 15th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.
08 by $0.02. The firm had revenue of $95.
70 million during the quarter, compared to analysts’ expectations of $91.94 million. Cellebrite DI had a positive return on equity of 5,902.
06% and a negative net margin of 28.51%. Cellebrite DI’s revenue for the quarter was up 24.
8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.05 EPS.
Sell-side analysts anticipate that Cellebrite DI will post 0.31 earnings per share for the current fiscal year. About Cellebrite DI ( Get Free Report Cellebrite DI Ltd.
develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft. Further Reading Five stocks we like better than Cellebrite DI Best Aerospace Stocks Investing CarMax’s Impressive Rally: What Investors Should Watch Next 3 Fintech Stocks With Good 2021 Prospects MarketBeat Week in Review – 9/23 – 9/27 What is a Stock Market Index and How Do You Use Them? Wake Up to This Biotech Stock That Still Has Big Potential Upside Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.
com's FREE daily email newsletter ..
